A new UK company set up by entrepreneur Bryan Morton to develop an innovative medicine for ankylosing spondylitis may be an example of how start-up companies could be supported through the UK's just announced industrial strategy for the life sciences sector.
A management team led by serial entrepreneur Bryan Morton has set up a new UK-based company, Izana Bioscience, with a focus on translational medicine and a lead compound, a GM-CSF targeting antibody, namilumab (IZN-101), set to enter a Phase II proof-of-concept study in ankylosing spondylitis.
It’s the latest in a series of companies set up by Morton and colleagues, that include Zeneus Pharma Ltd.,...
Create an account to read this article
Already a subscriber?
The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.
Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.
Shares of the Palo Alta, CA-based firm fell as Attruby sales missed elevated investor expectations in the second full quarter since its launch.
CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.
CEO Robert Bradway expressed support on the company’s Q2 earnings call for lower drug prices but said it was “premature” to comment in detail on particular proposals.
